search

Active clinical trials for "Glaucoma"

Results 441-450 of 1636

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate...

Glaucoma and Ocular Hypertension

The purpose of this study is to determine the intraocular Pressure (IOP) lowering response and evaluate the safety of brimonidine tartrate 0.025% ophthalmic solution in adult subjects with open angle glaucoma or ocular hypertension.

Completed7 enrollment criteria

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

GlaucomaOcular Hypertension

The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.

Completed18 enrollment criteria

AqueSys Microfistula Implant in Refractory Glaucoma

GlaucomaGlaucoma1 more

To establish the safety and performance of the AqueSys Microfistula Implant in eyes with refractory glaucoma.

Completed10 enrollment criteria

ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG)...

Primary Open Angle GlaucomaOcular Hypertension

This single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular Hypertension

Completed11 enrollment criteria

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With...

Ocular Hypertension (OHT)Mild Open Angle-glaucoma (OAG)

The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG). The secondary objectives are to evaluate Pharmacodynamics (PD) and to characterize the pharmacokinetic (PK) profile of ONO-9054 and its metabolite in plasma and to compare its tolerability following morning and evening dosing.

Completed9 enrollment criteria

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution...

Ocular HypertensionPrimary Open-Angle Glaucoma

This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days. Part 2 will evaluate the safety and IOP effects of a formulation (to be selected from part 1) of AGN-210961 in both eyes compared to bimatoprost ophthalmic solution 0.03% for 4 weeks.

Completed5 enrollment criteria

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and...

GlaucomaOcular Hypertension

The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.

Completed8 enrollment criteria

Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

Normal Tension Glaucoma

To prove the non-inferiority of the fixed timolol-dorzolamide combination (Cosopt) compared to 0.005% latanoprost (Xalatan) in the aspects of intraocular pressure (IOP) and ocular perfusion pressure (OPP) in subjects with normal tension glaucoma (NTG) Clinical hypotheses. Primary hypothesis Cosopt group is non-inferior to Xalatan group in diurnal IOP reduction. Secondary hypothesis Cosopt group is non-inferior to Xalatan group in diurnal diastolic and systolic OPP.

Completed16 enrollment criteria

Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular...

GlaucomaOcular Hypertension

Subjects are dosed twice daily at 9AM and 9PM for 12 weeks. The primary efficacy variable is the mean change in Intraocular Pressure (IOP) from baseline to 12 weeks. Secondary efficacy variable: % IOP ≤ 18 millimeters mercury (mmHg). Exploratory endpoint: Ocular discomfort scale after first dose.

Completed14 enrollment criteria

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma...

Open-Angle GlaucomaOcular Hypertension

This study will evaluate the safety and efficacy of new ophthalmic formulations of bimatoprost in patients with open angle glaucoma and ocular hypertension. At least 3 dose strengths will be evaluated based on internal data review of each cohort. The study was planned to be conducted in 2 stages. Stage 1 was an open-label and Stage 2 was planned to be masked; however only Stage 1 was conducted.

Completed3 enrollment criteria
1...444546...164

Need Help? Contact our team!


We'll reach out to this number within 24 hrs